Dateline City:
WHITEHOUSE STATION, N.J.
Data are Embargoed by American Heart Association until 10:45 AM CT Today
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today said that IMPROVE-IT met its primary endpoint. The results are
scheduled to be presented at the American Heart Association Scientific
Sessions later today. The data are embargoed by the American Heart
Association until the start of the late-breaking clinical trials session
at 10:45 a.m. CT today.
About Merck
Language:
English
Contact:
MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more